sábado, 14 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 30, 2026

Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades

View original at globenewswire.com
Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades GEORGE TOWN, Cayman Islands, June 30, 2026 (GLOBE NEWSWIRE) -- The first half of 2026 for Toobit has been defined by a focus on building products that help traders navigate markets…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Toobit achieved an AAA security rating, placing it among the top 10 most secure crypto exchanges globally, with perfect 100/100 scores in server security, user security, penetration testing, and bug bounty management

    60% confidence

  • Toobit was named Digital Asset Derivatives Platform of the Year for the second consecutive year following a rigorous selection process combining expert panel vetting with extensive industry voting

    60% confidence

  • As Toobit enters the second half of 2026, the focus shifts toward expanding the TradFi portfolio and scaling AI-assisted trading tools

    60% confidence

  • Toobit captured a top 10 position globally per the CoinGecko 2026 CEX & DEX Trading Report, demonstrating deep liquidity and high user engagement across spot and perps markets

    60% confidence

  • Hacken's audit confirmed a collateral ratio exceeding 100% across all in-scope digital assets

    60% confidence

Data points we hold from this source

XRP · earn apr offered30 percent
Bitcoin · earn apr offered30 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Toobit 2026 H1 Review: TradFi, Futures, & AI Trading Upgrades — Source | Via News | pt.VIA.NEWS